Oral chemotherapy with vinorelbine for advanced breast cancer: its role in clinical practice


DOI: https://dx.doi.org/10.18565/pharmateca.2019.7.96-101

D.D. Sakaeva (1, 2), A.F. Nasretdinov (1)

1) Republican Clinical Oncologic Dispensary, Ufa, Russia; 2) Bashkir State Medical University, Department of Pharmacology with a Course of Clinical Pharmacology, Ufa, Russia
Background. The article discusses options for managing patients with metastatic breast cancer, depending on the characteristics of the tumor, the patient’s condition, and the presence of comorbidities. The advantages and features of oral chemotherapy are discussed.
Description of the clinical case. A clinical case of the use of oral vinorelbine in patient with left-sided breast cancer of the left in real clinical practice is described. After five courses of neoadjuvant polychemotherapy, external-beam radiotherapy, left-sided mastectomy, adjuvant hormone therapy with tamoxifen in the postoperative period, the progression of the disease was registered. Treatment with oral vinorelbine was adminestered. After achieving remission, the patient was pescribed fulvestrant maintenance therapy.
Conclusion. In terms of treatment options, the use of oral chemotherapy drugs such as capecitabine and oral vinorelbine is of interest. The latter allow control of the disease, are well tolerated, and reduce the time and costs associated with treatment.
Keywords: metastatic breast cancer, oral therapy, vinorelbine

About the Autors


Corresponding author: Dina D. Sakaeva, MD, Deputy Chief Physician for Chemotherapy, Republican Clinical Oncologic Dispensary, Ufa, Russia; e-mail: d_sakaeva@mail.ru
Address: 73/1, Prospekt Oktyabrya, Ufa 450054, Russian Federation


Бионика Медиа